Management of Hypertriglyceridemia in Patients on High-Dose Statin Therapy

Primary Recommendation: Icosapent Ethyl

The American College of Cardiology recommends icosapent ethyl 2g twice daily for patients with fasting triglycerides 135-499 mg/dL, LDL-C 41-100 mg/dL, on moderate or high-intensity statin therapy, with HbA1c <10%, and no history of pancreatitis, atrial fibrillation, or severe heart failure, based on proven cardiovascular risk reduction 1
The REDUCE-IT trial demonstrated a 25% reduction in major adverse cardiovascular events when icosapent ethyl was added to statin therapy in high-risk patients with elevated triglycerides 1, 2

The European Society of Cardiology suggests fenofibrate can be added to statin therapy when icosapent ethyl criteria are not met or for severe hypertriglyceridemia, particularly in diabetic patients with poor glycemic control 3, 4
Fenofibrate is recommended for severe hypertriglyceridemia (≥500 mg/dL) requiring urgent triglyceride reduction to prevent pancreatitis, and for diabetic patients with poorly controlled glucose (HbA1c ≥10%) and elevated triglycerides 4, 6

For moderate hypertriglyceridemia (135-499 mg/dL), the first priority is to optimize lifestyle factors and address secondary causes, followed by ensuring maximally tolerated statin therapy, and then adding icosapent ethyl 2g twice daily if criteria are met 2, 1
For severe hypertriglyceridemia (≥500 mg/dL), immediate interventions include a very low-fat diet, absolute alcohol avoidance, and optimizing glycemic control, followed by initiating fenofibrate to prevent acute pancreatitis 3, 4

The American Diabetes Association recommends improving glycemic control as the highest priority for diabetic patients, as it can significantly reduce triglycerides, and suggests fenofibrate is particularly useful in diabetic patients with combined hyperlipidemia 6, 7
The American College of Cardiology recommends considering persistently elevated triglycerides (≥175 mg/dL) as a risk-enhancing factor favoring intensification of therapy in patients with ASCVD or high CV risk 2